摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,2S,3R)-1-(2-(4-ethylisoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol | 1258592-16-3

中文名称
——
中文别名
——
英文名称
(1R,2S,3R)-1-(2-(4-ethylisoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol
英文别名
(1R,2S,3R)-1-[2-(4-ethyl-1,2-oxazol-3-yl)-1H-imidazol-5-yl]butane-1,2,3,4-tetrol
(1R,2S,3R)-1-(2-(4-ethylisoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol化学式
CAS
1258592-16-3
化学式
C12H17N3O5
mdl
——
分子量
283.284
InChiKey
ZIGOZRPJKIQYFW-FBIMIBRVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.7
  • 重原子数:
    20
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    136
  • 氢给体数:
    5
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    在 10% palladium on activated charcoal 、 氢气sodium methylate溶剂黄146 作用下, 以 甲醇乙醇 为溶剂, 反应 43.0h, 生成 (1R,2S,3R)-1-(2-(4-ethylisoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol
    参考文献:
    名称:
    Inhibition of Sphingosine 1-Phosphate Lyase for the Treatment of Rheumatoid Arthritis: Discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime (LX2931) and (1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)
    摘要:
    Sphingosine 1-phosphate lyase (S1PL) has been characterized as a novel target for the treatment of autoimmune disorders using genetic and pharmacological methods. Medicinal chemistry efforts targeting S1PL by direct in vivo evaluation of synthetic analogues of 2-acetyl-4(5)-(1(R),2(S),3(R),4-tetrahydroxy-butyl)-imidazole (THI, 1) led to the discovery of 2 (LX2931) and 4 (LX2932). The immunological phenotypes observed in S1PL deficient mice were recapitulated by oral administration of 2 or 4. Oral dosing of 2 or 4 yielded a dose-dependent decrease in circulating lymphocyte numbers in multiple species and showed a therapeutic effect in rodent models of rheumatoid arthritis (RA). Phase I clinical trials indicated that 2, the first clinically studied inhibitor of S1PL, produced a dose-dependent and reversible reduction of circulating lymphocytes and was well tolerated at dose levels of up to 180 mg daily. Phase II evaluation of 2 in patients with active rheumatoid arthritis is currently underway.
    DOI:
    10.1021/jm101183p
点击查看最新优质反应信息